Drug Development

Pharmalot By Ed Silverman

Lawmakers ask Defense Department about using a controversial maneuver to lower drug prices

Pharmalot By Ed Silverman

Pharmalittle: Biogen yanks Alzheimer’s paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales

Pharmalot By Ed Silverman

Animal rights activists get new ammunition in their battle over a controversial rodent test

Pharmalot By Ed Silverman

Pharmalittle: Pharma lobbies Congress on global tax proposal; the FDA doc at center of Aduhelm controversy

Pharmalot By Ed Silverman

Pharmalittle: A race to develop Covid-19 pills is underway; Russian trolls target Pfizer vaccine

Biotech By Adam Feuerstein

Cytokinetics drug improves blood flow in patients with inherited form of heart disease

The Pharmalot View By Ed Silverman

Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels

STAT Summit By Megan Molteni

Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Pharmalot By Ed Silverman

FDA extends shelf life for glaucoma drug discontinued by Pfizer, but patients remain concerned

Exclusive By Nicholas Florko, Ed Silverman, Rachel Cohrs, and Damian Garde

FDA’s expansive Alzheimer’s drug approval surprised even top agency officials

Pharmalot By Ed Silverman

Former Genentech scientist convicted of stealing trade secrets given to former JHL Biotech execs

First Opinion By Emil D. Kakkis

Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases

First Opinion By Margaret Goldberg

Patient advocacy groups and innovators must partner to advance new treatments

Pharmalot By Ed Silverman

Regulators in many European countries fail to ensure clinical trial data are available

Biotech By Kate Sheridan

Nestlé Health Science will split profits from Seres microbiome drug, if it’s approved

Biotech By Adam Feuerstein

The biotech scorecard for the third quarter: 12 stock-moving events to watch

Health By Helen Branswell

12 lessons Covid-19 taught us about developing vaccines during a pandemic

Pharmalot By Ed Silverman

Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?

First Opinion By Sevahn Vorperian and Stephen Quake

The PASTEUR Act can help win the war against superbugs

Pharma By Ed Silverman

Drug-resistant bacteria pose a growing threat. Can new antibiotics be developed fast enough to combat them?

First Opinion By Calaneet Balas

FDA should lead the way on new ALS treatments, not Canada and Europe

In the Lab By Megan Molteni

Scientists unshelve a decades-old antibiotic to fight a new foe — ovarian cancer

Biotech By Kate Sheridan

Virtual Event – Biotech: Where are we now?

First Opinion Podcast By Patrick Skerrett

Most Read

Microbiome therapy companies face the fallout of failed Seres trial

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

Seres Therapeutics’ microbiome therapy for ulcerative colitis falls short in Phase 2 trial

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

Patient advocacy organizations and FDA drug approval: lessons from Aduhelm

How nanotechnology helps mRNA Covid-19 vaccines work

Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups

Luck is not a strategy: The world needs to start preparing now for the next pandemic

All Coverage

Lawmakers ask Defense Department about using a controversial maneuver to lower drug prices

Pharmalittle: Biogen yanks Alzheimer’s paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales

Animal rights activists get new ammunition in their battle over a controversial rodent test

Pharmalittle: Pharma lobbies Congress on global tax proposal; the FDA doc at center of Aduhelm controversy

Pharmalittle: A race to develop Covid-19 pills is underway; Russian trolls target Pfizer vaccine

Cytokinetics drug improves blood flow in patients with inherited form of heart disease

Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels

Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

FDA extends shelf life for glaucoma drug discontinued by Pfizer, but patients remain concerned

FDA’s expansive Alzheimer’s drug approval surprised even top agency officials

Former Genentech scientist convicted of stealing trade secrets given to former JHL Biotech execs

Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases

Patient advocacy groups and innovators must partner to advance new treatments

Regulators in many European countries fail to ensure clinical trial data are available

Nestlé Health Science will split profits from Seres microbiome drug, if it’s approved

The biotech scorecard for the third quarter: 12 stock-moving events to watch

12 lessons Covid-19 taught us about developing vaccines during a pandemic

Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?

The PASTEUR Act can help win the war against superbugs

Drug-resistant bacteria pose a growing threat. Can new antibiotics be developed fast enough to combat them?

FDA should lead the way on new ALS treatments, not Canada and Europe

Scientists unshelve a decades-old antibiotic to fight a new foe — ovarian cancer

Virtual Event – Biotech: Where are we now?

Listen: Two Alzheimer’s experts with opposing viewpoints on Aduhelm

drug development

Most Read

All Coverage